首页> 美国卫生研究院文献>European Heart Journal >Fast TrackEditors choice: Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial
【2h】

Fast TrackEditors choice: Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial

机译:Fast TrackEditor的选择:慢性缺血性心力衰竭患者单次施用基质细胞衍生的因子1非病毒基因治疗后一年内的心室重构和临床状况变化:STOP-HF随机II期临床试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundStromal cell-derived factor-1 (SDF-1) promotes tissue repair through mechanisms of cell survival, endogenous stem cell recruitment, and vasculogenesis. Stromal Cell-Derived Factor-1 Plasmid Treatment for Patients with Heart Failure (STOP-HF) is a Phase II, double-blind, randomized, placebo-controlled trial to evaluate safety and efficacy of a single treatment of plasmid stromal cell-derived factor-1 (pSDF-1) delivered via endomyocardial injection to patients with ischaemic heart failure (IHF).
机译:背景星形细胞衍生因子1(SDF-1)通过细胞存活,内源性干细胞募集和血管生成机制促进组织修复。心力衰竭患者基质细胞衍生因子-1质粒治疗(STOP-HF)是一项II期,双盲,随机,安慰剂对照试验,旨在评估质粒基质细胞衍生因子单一治疗的安全性和有效性-1(pSDF-1)通过心内膜内注射输送给缺血性心力衰竭(IHF)患者。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号